Acrizanib
Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-VEGFR-2[1].
Product Specifications
CAS Number
[1229453-99-9]
Product Name Alternative
LHA510
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/Acrizanib.html
Purity
99.84
Solubility
DMSO : 41.67 mg/mL (ultrasonic)
Smiles
O=C(N1C2=CC=C(OC3=NC=NC(CNC)=C3)C=C2C=C1)NC4=NN(C)C(C(F)(F)F)=C4
Molecular Formula
C20H18F3N7O2
Molecular Weight
445.40
Precautions
H302, H315, H319, H335
References & Citations
[1]Adams CM, et al. The Discovery of N- (1-Methyl-5- (trifluoromethyl) -1H-pyrazol-3-yl) -5- ((6- ((methylamino) methyl) pyrimidin-4-yl) oxy) -1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration. J Med Chem. 2018 Feb 22;61 (4) :1622-1635.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
VEGFR2/KDR/Flk-1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
